Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
The Wellness Center of Greater Cleveland will evaluate each patients case individually in order to determine if they are a suitable candidate for Semaglutide
Ragsdale LB et al
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
Set up in 1987 in San Diego, Amylin was a small biotechnology company already developing another diabetic drug and agreed to take the gamble with Raufman and Eng's peptide
Validation studies include day-to-day repeatability assessment (8.3-8.4% RSD for signal-to-background and EC 50 ), inter-analyst reproducibility testing, relative potency evaluation across 50-150% nominal concentrations, and dilutional linearity analysis (R 2 = 0.9990)
US$ 23.49
US$ 28.50
US$ 25.62
US$ 28.12
US$ 28.65
